8.65
price up icon1.53%   0.13
pre-market  Vorhandelsmarkt:  8.68   0.03   +0.35%
loading
Schlusskurs vom Vortag:
$8.52
Offen:
$8.49
24-Stunden-Volumen:
3.89M
Relative Volume:
0.88
Marktkapitalisierung:
$1.81B
Einnahmen:
$503.49M
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-33.27
EPS:
-0.26
Netto-Cashflow:
$-26.89M
1W Leistung:
-0.80%
1M Leistung:
-14.36%
6M Leistung:
+13.52%
1J Leistung:
+16.58%
1-Tages-Spanne:
Value
$8.40
$8.69
1-Wochen-Bereich:
Value
$8.40
$8.80
52-Wochen-Spanne:
Value
$6.015
$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
Firmenname
Biocryst Pharmaceuticals Inc
Name
Telefon
919-859-1302
Name
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
Mitarbeiter
580
Name
Twitter
@biocrystpharma
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
BCRX's Discussions on Twitter

Vergleichen Sie BCRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
8.65 1.82B 503.49M -53.47M -26.89M -0.26
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
151.19 68.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.55 46.58B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.65 43.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.29 18.40B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
297.89 13.23B 2.99B 1.21B 1.13B 25.06

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-02-25 Eingeleitet Wedbush Outperform
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-09-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-08-04 Hochstufung Jefferies Hold → Buy
2023-07-13 Hochstufung BofA Securities Neutral → Buy
2023-02-22 Hochstufung Needham Hold → Buy
2022-11-02 Hochstufung Evercore ISI In-line → Outperform
2022-08-05 Herabstufung Evercore ISI Outperform → In-line
2022-08-05 Herabstufung Oppenheimer Outperform → Perform
2022-04-18 Herabstufung Barclays Overweight → Equal Weight
2022-04-11 Herabstufung BofA Securities Buy → Neutral
2021-12-10 Eingeleitet Oppenheimer Outperform
2021-08-06 Herabstufung Jefferies Buy → Hold
2021-08-03 Eingeleitet Cantor Fitzgerald Overweight
2021-03-01 Eingeleitet Cowen Outperform
2020-09-29 Fortgesetzt JP Morgan Overweight
2020-06-17 Eingeleitet BTIG Research Neutral
2020-05-05 Hochstufung Barclays Equal Weight → Overweight
2019-11-15 Hochstufung BofA/Merrill Neutral → Buy
2019-05-24 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2018-11-16 Fortgesetzt Piper Jaffray Overweight
2018-08-08 Fortgesetzt JP Morgan Overweight
2018-07-17 Hochstufung BofA/Merrill Underperform → Neutral
2018-06-22 Eingeleitet Seaport Global Securities Neutral
2018-01-02 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2017-12-20 Eingeleitet Barclays Equal Weight
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-09-06 Hochstufung JP Morgan Neutral → Overweight
2017-09-06 Hochstufung Jefferies Hold → Buy
2017-02-16 Eingeleitet Ladenburg Thalmann Buy
2016-08-12 Hochstufung Piper Jaffray Neutral → Overweight
2016-08-04 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Bestätigt FBR Capital Outperform
2016-02-09 Herabstufung JP Morgan Overweight → Neutral
2016-02-09 Herabstufung Needham Buy → Hold
Alle ansehen

Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten

pulisher
Jul 22, 2025

BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Is BioCryst Pharmaceuticals Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 20, 2025

BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Management Insights - printweek.in

Jul 20, 2025
pulisher
Jul 20, 2025

What drives BioCryst Pharmaceuticals Inc. stock priceFree Capital Efficiency Planning - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

How To Trade (BCRX) - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

BioCryst appoints Babar Ghias as CFO - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsCarefully Curated High Return Stocks - beatles.ru

Jul 18, 2025
pulisher
Jul 17, 2025

BioCryst Pharmaceuticals (BCRX) Rallies 1.28% Amid Analyst Coverage - AInvest

Jul 17, 2025
pulisher
Jul 15, 2025

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 14, 2025

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail

Jul 14, 2025
pulisher
Jul 13, 2025

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN

Jul 13, 2025
pulisher
Jul 10, 2025

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan

Jul 09, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com

Jul 08, 2025
pulisher
Jul 08, 2025

BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Island Pharmaceuticals Acquires Galidesivir Antiviral Program from BioCryst Pharmaceuticals - AInvest

Jul 08, 2025
pulisher
Jul 07, 2025

CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com

Jul 07, 2025
pulisher
Jul 07, 2025

Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech

Jul 07, 2025
pulisher
Jul 07, 2025

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO. - AInvest

Jul 07, 2025
pulisher
Jul 06, 2025

BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus

Jul 06, 2025
pulisher
Jul 06, 2025

BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey

Jul 06, 2025
pulisher
Jul 05, 2025

10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey

Jul 05, 2025
pulisher
Jul 03, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025
pulisher
Jul 03, 2025

BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan

Jul 03, 2025
pulisher
Jul 01, 2025

BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 30, 2025

BioCryst Pharma (BCRX) Maintains Outperform Rating and $13 Price Target | BCRX Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 30, 2025

BCRX Stock Rating and Price Target Update by Wedbush | BCRX Stoc - GuruFocus

Jun 30, 2025

Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.34
price up icon 1.09%
$14.93
price up icon 1.70%
$9.24
price up icon 3.82%
drug_manufacturers_specialty_generic RDY
$14.41
price down icon 0.96%
$132.75
price up icon 0.70%
$297.89
price up icon 1.63%
Kapitalisierung:     |  Volumen (24h):